Terms: = Prostate cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Treatment
55 results:
1. A cxcr4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis.
Robinson T; Escara-Wilke J; Dai J; Zimmermann J; Keller ET
Prostate; 2023 Sep; 83(13):1247-1254. PubMed ID: 37244751
[TBL] [Abstract] [Full Text] [Related]
2. Interstitial fluid flow contributes to prostate cancer invasion and migration to bone; study conducted using a novel horizontal flow bioreactor.
Jasuja H; Jaswandkar SV; Katti DR; Katti KS
Biofabrication; 2023 Mar; 15(2):. PubMed ID: 36863017
[TBL] [Abstract] [Full Text] [Related]
3. Dynamics of cxcr4 positive circulating tumor cells in prostate cancer patients during radiotherapy.
Klusa D; Lohaus F; Franken A; Baumbach M; Cojoc M; Dowling P; Linge A; Offermann A; Löck S; Hušman D; Rivandi M; Polzer B; Freytag V; Lange T; Neubauer H; Kücken M; Perner S; Hölscher T; Dubrovska A; Krause M; Kurth I; Baumann M; Peitzsch C
Int J Cancer; 2023 Jun; 152(12):2639-2654. PubMed ID: 36733230
[TBL] [Abstract] [Full Text] [Related]
4. pH-sensitive nanoliposomes for passive and CXCR-4-mediated marine yessotoxin delivery for cancer therapy.
Vieira AM; Silvestre OF; Silva BF; Ferreira CJ; Lopes I; Gomes AC; Espiña B; Sárria MP
Nanomedicine (Lond); 2022 Apr; 17(10):717-739. PubMed ID: 35481356
[No Abstract] [Full Text] [Related]
5. Role of Resveratrol as Radiosensitizer by Targeting cancer Stem Cells in Radioresistant prostate cancer Cells (PC-3).
El-Benhawy SA; Morsi MI; Fahmy EI; Soula MA; Khalil FAZF; Arab AR
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3823-3837. PubMed ID: 34967561
[TBL] [Abstract] [Full Text] [Related]
6. Triterpenoid ursolic acid drives metabolic rewiring and epigenetic reprogramming in treatment/prevention of human prostate cancer.
Li S; Wu R; Wang L; Dina Kuo HC; Sargsyan D; Zheng X; Wang Y; Su X; Kong AN
Mol Carcinog; 2022 Jan; 61(1):111-121. PubMed ID: 34727410
[TBL] [Abstract] [Full Text] [Related]
7. The Embryonic Key Pluripotent Factor NANOG Mediates Glioblastoma Cell Migration via the SDF1/cxcr4 Pathway.
Sánchez-Sánchez AV; García-España A; Sánchez-Gómez P; Font-de-Mora J; Merino M; Mullor JL
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638956
[TBL] [Abstract] [Full Text] [Related]
8. Insights into homeobox B9: a propeller for metastasis in dormant prostate cancer progenitor cells.
Sui Y; Hu W; Zhang W; Li D; Zhu H; You Q; Zhu R; Yi Q; Tang T; Gao L; Zhu S; Yang T
Br J Cancer; 2021 Sep; 125(7):1003-1015. PubMed ID: 34247196
[TBL] [Abstract] [Full Text] [Related]
9. New perspectives of quercetin and vitamin C effects on fibronectin-binding integrins and chemokine receptors in prostate cancer cell lines.
Amiri A; Abbasi A; Dehghani M; Ramezani A; Ramezani F; Zal F; Mostafavi-Pour Z
Bratisl Lek Listy; 2021; 122(7):507-512. PubMed ID: 34161119
[TBL] [Abstract] [Full Text] [Related]
10. The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers.
Midavaine É; Côté J; Sarret P
Cancer Metastasis Rev; 2021 Jun; 40(2):427-445. PubMed ID: 33973098
[TBL] [Abstract] [Full Text] [Related]
11. Sequential Release of Pooled siRNAs and Paclitaxel by Aptamer-Functionalized Shell-Core Nanoparticles to Overcome Paclitaxel Resistance of prostate cancer.
Guo Q; Dong Y; Zhang Y; Fu H; Chen C; Wang L; Yang X; Shen M; Yu J; Chen M; Zhang J; Duan Y
ACS Appl Mater Interfaces; 2021 Mar; 13(12):13990-14003. PubMed ID: 33739080
[TBL] [Abstract] [Full Text] [Related]
12. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract] [Full Text] [Related]
13. Dual cxcr4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in prostate cancer Cell Intraosseous Growth.
Festuccia C; Mancini A; Gravina GL; Colapietro A; Vetuschi A; Pompili S; Ventura L; Delle Monache S; Iorio R; Del Fattore A; Fogler W; Magnani J
Cells; 2019 Dec; 9(1):. PubMed ID: 31877673
[TBL] [Abstract] [Full Text] [Related]
14. Modulation of CXC-motif chemokine receptor 7, but not 4, expression is related to migration of the human prostate cancer cell LNCaP: regulation by androgen and inflammatory stimuli.
Yu L; Pham Q; Yu LL; Wang TTY
Inflamm Res; 2020 Feb; 69(2):167-178. PubMed ID: 31865399
[TBL] [Abstract] [Full Text] [Related]
15. β2AR-HIF-1α-CXCL12 signaling of osteoblasts activated by isoproterenol promotes migration and invasion of prostate cancer cells.
Huang Z; Li G; Zhang Z; Gu R; Wang W; Lai X; Cui ZK; Zeng F; Xu S; Deng F
BMC Cancer; 2019 Nov; 19(1):1142. PubMed ID: 31771535
[TBL] [Abstract] [Full Text] [Related]
16. Intercellular Crosstalk of Mesenchymal Stem Cells with prostate cancer Cells via Microvesicles Loaded with Magnetic Nanocubes for Targeted Magnetic Hyperthermia.
Huang L; Chen M; Xu C; Feng Q; Wu J; Gao L; Xu P; Ning P; Wen X; Cheng Y
J Biomed Nanotechnol; 2019 Dec; 15(12):2291-2304. PubMed ID: 31748012
[TBL] [Abstract] [Full Text] [Related]
17. Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and cxcr4 pathway.
Jang YG; Go RE; Hwang KA; Choi KC
J Steroid Biochem Mol Biol; 2019 Sep; 192():105406. PubMed ID: 31185279
[TBL] [Abstract] [Full Text] [Related]
18. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.
Schiano C; Soricelli A; De Nigris F; Napoli C
Expert Rev Clin Immunol; 2019 Mar; 15(3):289-301. PubMed ID: 30570412
[TBL] [Abstract] [Full Text] [Related]
19. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant prostate cancer.
Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
[TBL] [Abstract] [Full Text] [Related]
20. Bioinformatic analyses reveal the key pathways and genes in the cxcr4 mediated mesenchymal subtype of glioblastoma.
Yi L; Tong L; Li T; Hai L; Abeysekera IR; Tao Z; Ma H; Liu P; Xie Y; Li J; Yuan F; Yu S; Yang X
Mol Med Rep; 2018 Jul; 18(1):741-748. PubMed ID: 29767255
[TBL] [Abstract] [Full Text] [Related]
[Next]
